1. Introduction {#s0005}
===============

Periodontitis, the inflammation of the periodontium, affects 40--90% of the global population ([@b0155]). In the United States of America, it has been estimated that 46% of the adult population is affected by periodontitis ([@b0055]). Periodontitis is characterized by the progressive destruction of cementum, periodontal ligament and alveolar bone and subsequently, loss of teeth ([@b0220], [@b0140]). A number of factors contribute to periodontitis. Local factors such as poor oral hygiene and use of tobacco are found to be implicated in periodontal disease ([@b0140]) and tobacco ([@b0240], [@b0060]). Systemic conditions such as malnutrition ([@b0125]), diabetes, cardiovascular disease, infections ([@b0140]) and pregnancy ([@b0135], [@b0225]) may also lead to manifestation of periodontitis. Lack of oral hygiene leads in the formation of dental plaque ([@b0010], [@b0145]), a biofilm containing bacteria, lymphocytes, neutrophils, leuokocytes and macrophages. *Aggregatibacter actinomycetemcomitans*, *Porphyromonas gingivalis*, *Bacteroides forsythus*, *Prevotella intermedia*, *Campylobacter rectus*, *Eubacterium nodatum*, *Streptococcus intermedius* and *Treponema denticola* are the major bacteria that have been implicated in periodontitis ([@b0220], [@b0215], [@b0090]). The presence of bacteria leads to an exaggerated immune response which leads to destruction of periodontal tissues. This destruction of tissues triggers a release of cytokines from immune cells which promote inflammation. Secretion of these proinflammatory cytokines, for example IL-1β, is linked to the production of collagenase and prostaglandin E which play a part in bone destruction ([@b0190]). Management of chronic periodontitis mainly involves the removal of the causative factors and to repair, regenerate and maintain periodontal tissues. Scaling and root planing (SRP) is mainly used to remove plaque and calculus ([@b0050]). In SRP, debridement of supra- and subgingival plaque and calculus is carried out by ultrasonic and hand instruments, followed by smoothing of the exposed root surfaces. In some instances, SRP may be augmented by other treatments such as guided tissue regeneration, bone grafting and flap-procedures. Following SRP, antibiotics may be prescribed to treat the infection but may cause adverse effects ([@b0210]). In addition, guided tissue regeneration aims to regenerate bone by means of placing barrier membranes along with bone grafts and substitutes ([@b0200], [@b0030]). If the cause is systemic, measures should be taken to improve the overall health. Recently a number of agents such as melatonin ([@b0130], [@b0015]), platelet rich fibrin ([@b0120], [@b0005], [@b0160]) and metformin ([@b0160], [@b0175]) have been explored for the cure of periodontitis.

Metformin (1, 1-dimethylbiguanide) HCl (MF) is a second-generation biguanide, derived from French lilac (*Galega officinalis*), used to manage type 2 diabetes mellitus ([@b0245]). As an orally administered anti-hyperglycemic drug, it decreases blood glucose levels by inhibiting gluconeogesis (production of glucose) in the liver ([@b0230]). It has been suggested that MF inhibits intracellular binding of calcium at the mitochondria in the hepatocytes to decrease gluconeogenesis ([@b0195]). Moreover, MF is the drug of choice to treat type 2 diabetes mellitus in obese patients ([@b0070]). Studies have also shown favorable effect of MF on bone formation. There are two mechanisms of action that have been suggested for the osteogenic effect of MF: increased proliferation of osteoblasts and reduction of osteoclast activity. Studies indicate that after MF is taken up by osteoblasts, their proliferation is incrased ([@b0025], [@b0045]). In another study was observed that exposure to MF led to a decrease of osteoclast and bone formation. MF down-regulates the production of receptor activator of nuclear factor kappa B ligand (RANKL) and up-regulates the production of osteoprotegerin (OPG) from osteoblasts ([@b0110]). This decreased RANKL/OPG ratio in turn decreases the osteoclast activity, thereby inducing bone formation and inhibiting bone resorption. More recently, MF has been used as an adjunct to surgical and non-surgical periodontal therapy to treat chronic periodontitis ([@b0160], [@b0180]). Moreover, MF appears to augment the effect of platelet-rich fibrin in treating intrabony periodontal defects ([@b0160]). To the authors' best knowledge, there are no published systematic review studying the efficacy of MF therapy for treating periodontitis and related conditions. Hence, the aim of this review is to systematically evaluate the efficacy of MF in the treatment of periodontitis.

2. Methods {#s0010}
==========

2.1. Focused question {#s0015}
---------------------

Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines ([@b0115]), a focused question was constructed according to the Participants, Interventions, Control, Outcomes (PICO) principle ([@b0035]). The addressed focused question was: 'Is metformin (MF) effective in reducing bone loss in periodontitis?'

2.2. Criteria for selection of studies {#s0020}
--------------------------------------

The inclusion criteria for this review were: (1) original studies published in the English language, (2) animal studies, (3) clinical studies and (4) Intervention: topical or systemic MF to treat periodontitis. Following types of studies were excluded: (1) historic reviews, (2) letters to the editor, (3) case series and reports and (4) cell culture studies.

2.3. Search methodology {#s0025}
-----------------------

An electronic search was carried out using the keywords 'metformin', 'periodontal' and 'periodontitis' via the PubMed/Medline, ISI Web of Science and Google Scholar databases for relevant articles published from 1949 up to and including March 2016. The titles and abstracts of the articles found were read independently by two authors (S. N. and Z. K.). Both the authors checked for agreement via discussion. The references in the potentially relevant articles were read by both the authors to find additional studies which may not have been identified in the primary search following which the authors once again checked agreement via discussion. The search methodology is illustrated in the PRISMA flow diagram in [Fig. 1](#f0005){ref-type="fig"}.Fig. 1Selection process of studies (PRISMA flow diagram) used in this review.

2.4. Quality assessment and meta-analysis {#s0030}
-----------------------------------------

Each study was assessed for quality using the CONSORT principle by the two aforementioned reviewers (S. N. and Z. K.) ([@b0115]). Additionally, meta-analysis was conducted using R and meta package ([[http://CRAN.R-project.org/package = meta]{.ul}](http://CRAN.R-project.org/package=meta){#ir005}; <http://www.R-project.org>). Due to differences in concentration of Metformin or control group used in the studies, only 3 RCTs were included in the meta-analysis.

3. Results {#s0035}
==========

3.1. Search results {#s0040}
-------------------

Following the removal of the duplicate search results, the primary search resulted in 17 articles in total. Seven articles were excluded based on title and abstract. Hence, remaining ten articles were read completely for eligibility. After exclusion of another four irrelevant studies ([@b0095], [@b0205], [@b0075], [@b0105]) as shown in [Table 1](#t0005){ref-type="table"}, six studies ([@b0160], [@b0175], [@b0025], [@b0110], [@b0180], [@b0170]) were included in this review.Table 1List and reasoning of studies excluded from this review.Study (authors and year)Reason for exclusion[@b0205])Review[@b0095])Chinese language[@b0075])Review[@b0105])Case report

Two studies were animal studies ([@b0025], [@b0110]), and remaining fours studies were human trials ([@b0160], [@b0175], [@b0180], [@b0170]) as listed in [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}.Table 2Characteristic features of animal studies included in this review.Study (authors& year)Study designType of periodontal lesion(s)MethodsInterventionNumber of subject (*n*)Follow-upOutcomeControlTest[@b0025])*In vivo* prospectivePeriodontitis induced by ligatureHistological analysis, micro-CT analysis, cell assaysSalineMF (IP, 10 mg/kg body weight)10 rats10 daysSignificantly higher bone volume and less inflammation with MF. No effect of MF on osteoclasts and adipocytes. Higher number of osteoblasts with MF[@b0110])*In vivo* prospectivePeriapical lesions inducted by pulpal exposureHistological analysis, enzyme histo-chemistry, immunofluorescence labeling, immunohist-ochemistry, cell countingSalineMF (IM, 40 mg/kg body weight)40 rats28 daysRANKL/OPG ratio lower in test group. Significantly less osteoclasts seen in MF group[^1]Table 3General characteristics of the selected studies.Study, author and yearStudy designNumber of patientsNumber of smokersNumber of femalesNumber of IBDs included (*n*)Age, mean & range (years)Intervention and number of IBDs analysedFollow-up(weeks)Main outcome at follow upTest(*n*)Control(*n*)[@b0170])RCT4102111837.2\
(30--50)0.5% MF (26), 1% MF (27), 1.5% MF (29)SRP + 0% MF (26)6 monthsClinical and radiographic parameters were significantly better in test groups than control. 1% MF provided highest improvement[@b0180])RCT505007134.6 (30--50)1% MF (36)SRP + 0% MF (35)6 monthsClinical parameters and radiographic were significantly better in test groups than control[@b0175])RCT650386532.4 (25--50)1% MF (33)SRP + 0% MF (32)6 monthsClinical parameters and radiographic were significantly better in test groups than control[@b0160])RCT12006812041 (30--50)OFD + PRF (30), OFD + 1% MF (30), OFD + PRF + 1%MF (30)OFD (30)9 monthsClinical parameters and radiographic were significantly better in test groups than control. OFD + PRF+1% MF provided highest improvement[^2]Table 4Mean changes and clinical parameters reported by selected studies.Study (Authors and year)PD (mm) Mean ± SDRAL/CAL (mm) Mean ± SDGML (mm) Mean ± SDIBD depth (mm)Mean ± SDIBD fill (%)Mean ± SD[@b0170])0%MF + SRP1.77 ± 0.770%MF + SRP1.33 ± 0.66N/A0%MF + SRP1.19 ± 0.380%MF + SRP3.35 ± 8.360.5%MF + SRP2.96 ± 0.930.5%MF + SRP2.23 ± 0.73N/A0.5%MF + SRP1.03 ± 0.200.5%MF + SRP21.11 ± 3.811%MF + SRP4.0 ± 1.051%MF + SRP3.83 ± 0.95N/A1%MF + SRP1.57 ± 0.571%MF + SRP31.89 ± 10.261.5%MF + SRP3.8 ± 1.031.5%MF + SRP3.6 ± 0.81N/A1.5%MF + SRP1.38 ± 0.691.5%MF + SRP26.8 ± 5.52[@b0180])0%MF + SRP0.87 ± 0.940%MF + SRP1.47 ± 0.78N/A0%MF + SRP0.22 ± 0.380%MF + SRP3.75 ± 8.061%MF + SRP3.17 ± 0.751%MF + SRP3.27 ± 0.79N/A1%MF + SRP1.32 ± 0.41%MF + SRP26.17 ± 0.66[@b0175])0%MF + SRP2.0 ± 1.010%MF + SRP1.43 ± 0.97N/A0%MF + SRP0.23 ± 0.120%MF + SRP4.79 ± 2.31%MF + SRP3.96 ± 0.661%MF + SRP4.06 ± 0.86N/A1%MF + SRP1.35 ± 0.341%MF + SRP26.17 ± 0.66[@b0160])OFD3.00 ± 0.18OFD2.96 ± 0.18OFD- 0.06 ± 0.04OFD0.49 ± 0.27OFD9.14 ± 0.004OFD + PRP4.00 ± 0.18OFD + PRP4.03 ± 0.18OFD + PRP0.27 ± 0.07OFD + PRP2.53 ± 0.30OFD + PRP48 ± 0.029OFD + 1%MF3.93 ± 0.25OFD + 1%MF3.83 ± 0.25OFD + 1%MF0.27 ± 0.05OFD + 1%MF2.56 ± 0.28OFD + 1%MF48.69 ± 0.026OFD + 1%MF + PRF4.90 ± 0.30OFD + 1%MF + PRF4.90 ± 0.30OFD + 1%MF + PRF0.33 ± 0.07OFD + 1%MF + PRF2.77 ± 0.3OFD + 1%MF + PRF52.65 ± 0.031[^3]

3.2. Animal studies {#s0045}
-------------------

Both the animal studies were *in vivo* prospective studies ([@b0025], [@b0110]). The number of animals used as test subjects ranged from 10 to 40 ([@b0025], [@b0110]). In one study, periapical periodontitis was induced by intentionally perforating the pulpal floor of the teeth ([@b0110]) and in the other study, chronic periodontitis was induced by means of ligatures ([@b0025]). MF was injected intraperitoneally (IP) to the periapical region in doses of 10 mg/kg body weight in one study ([@b0025]) while it was administered to the animals via intramuscular (IM) injections in doses of 40 mg/kg body weight in the other study ([@b0110]). The follow-up period ranged from 10 to 28 days ([@b0025], [@b0110]). Saline was used as control in both the studies ([@b0025], [@b0110]). The general characteristics of the animal studies are provided in [Table 2](#t0010){ref-type="table"}.

3.3. Human studies {#s0050}
------------------

All human studies were randomized control trials (RCTs) ([@b0160], [@b0175], [@b0180], [@b0170]). Number of patients included the studies ranged from 41 to 120 in which the number of female subjects ranged from 0 to 68 ([@b0160], [@b0175], [@b0180], [@b0170]). Only one study included smokers which were 50 in number ([@b0180]). The age of the patients ranged from 25 to 50 years ([@b0160], [@b0175], [@b0180], [@b0170]). In all studies, MF gel was used in combination with other treatment modalities ([@b0160], [@b0175], [@b0180], [@b0170]). Concentration of MF ranged from 0.5 to 1.5% ([@b0160], [@b0175], [@b0180], [@b0170]). MF gel was injected into periodontal defects combination with scaling and root planing in 3 studies (SRP + MF) ([@b0175], [@b0180], [@b0170]) and was applied in combination with open-flap debridement (OFD) in one study ([@b0160]). In one study, 1% MF was used in combination with platelet-rich fibrin (PRF) and OFD (1%MF + PRP + OFD) as intervention ([@b0160]). Also, PRF was used as an adjunct to OFD in one study as intervention (OFD + PRF) ([@b0160]). As controls, SRP combined with placebo gel (SRP + 0% MF) was used in 3 studies ([@b0175], [@b0180], [@b0170]) while in one study OFD was used ([@b0160]). The follow-up period was 6 months in 3 studies ([@b0175], [@b0180], [@b0170]), while in one study the patients were followed-up for 9 months ([@b0160]). A summary of the general characteristics of RCTs is provided in [Table 3](#t0015){ref-type="table"}.

3.4. Assessment of parameters {#s0055}
-----------------------------

In both animal studies, histological analysis, cell number and enzyme assays were used as primary parameters assessed ([@b0025], [@b0110]). In one study, micro-CT analysis was also used ([@b0025]). Mean changes in probing depth (PD), relative or clinical attachment level (RAL/CAL), intrabony defect depth (IBD depth) and intrabony defect fill (IBD fill) were measured by all human studies ([@b0160], [@b0175], [@b0180], [@b0170]). Only one study measured mean changes in gingival marginal levels (GML) in addition to PD, RAL/CAL, IBD depth and IBD fill ([@b0160]). Plaque index (PI) and modified sulcular bleeding index (mSBI) measured as a parameter of oral hygiene by all clinical studies ([@b0160], [@b0175], [@b0180], [@b0170]). One study measured the level of MF in the gingival crevicular fluid (GCF), following treatment with 0.5%, 1% and 1.5% MF along with SRP, for a period of 28 days ([@b0170]).

3.5. Main outcomes of the selected studies {#s0060}
------------------------------------------

Results from all 6 studies show that using MF is effective in reducing bone loss and improving outcomes of periodontal treatment ([@b0160], [@b0175], [@b0025], [@b0110], [@b0180], [@b0170]). In both animal studies, IP and IM injections of MF led to more favorable results when compared to saline controls ([@b0025], [@b0110]). IP injections of MF in doses of 10 mg/kg body weight resulted in a significantly higher number of osteoblasts and reduced bone loss but did not have significant effect on the number of adipocytes and osteoclasts ([@b0025]). On the other hand, IM injections of MF in doses of 40 mg/kg body weight resulted in lower RANKL/OPG ratios and reduced number of osteoclasts in addition to diminished bone loss ([@b0110]). In clinical studies, 1%MF + SRP and 1%MF + OFD resulted in better clinical and radiographic outcomes than SRP and OFD alone ([@b0160], [@b0175], [@b0180], [@b0170]). 1%MF + SRP resulted in better outcomes and higher MF levels in GCF than 0.5%MF + SRP and 1.5%MF + SRP ([@b0170]). Additionally, OFD + 1%MF + PRF resulted in significantly higher improvement in parameters than PRF + OFD, 1%MF + OFD and OFD ([@b0160]). After 6 month follow-up, the highest IBD fill was demonstrated by 1%MF + SRP (26.1--31.89%) ([@b0175], [@b0180], [@b0170]) and the lowest was shown with 0%MF + SRP (4.79--3.35%) ([@b0175], [@b0180], [@b0170]). After 9 month follow-up, the highest IBD fill was exhibited with OFD + 1%MF + PRF (52.65%) and the lowest IBD fill was seen with OFD (9.14%) ([@b0160]). In three studies, when compared to SRP alone, application of MF along with SRP led to higher improvement in pocket depth (PD). The improvement in PD ranged from 2.96 mm to 4,0 mm ([@b0160], [@b0180], [@b0170]). Additionally, addition of MF application to OFD also resulted in improved PD when compared to OFD alone in one study ([@b0160]). The highest improvement in PD was exhibited by application of 1%MF and PRF along with OFD ([@b0160]). In all studies, application of MF to surgical or non surgical periodontal therapy resulted in improvement IBD depth and IBD fill. The highest improvement in IBD depth and IBD fill was observed to be 2.77 mm and 52.6% respectively following application of 1%MF and PRF with OFD ([@b0160]). The mean changes in clinical parameters are summarized in [Table 4](#t0020){ref-type="table"}.

3.6. Meta-analysis {#s0065}
------------------

The results of the meta-analysis results are summarized in [Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}. SRP + 1% MF resulted in significantly higher improvements in all assessed clinical parameters. However, the I^2^ statistic values for CAL/RAL, IBD fill and IBD were higher than 50, indicating heterogeneity among the results ([Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}).Fig. 2Meta-analysis reporting changes in clinical/relative attachment levels.Fig. 3Meta-analysis reporting changes in intra-bony defect fill.Fig. 4Meta-analysis reporting changes in intra-bony defect depth.Fig. 5Meta-analysis reporting changes in pocket depth.

On the other hand, since meta-analysis of PD values demonstrated I^2^ statistic of less than 50, 1% MF application following SRP was found to have the highest impact on PD compared to other clinical parameters.

4. Discussion {#s0070}
=============

In all of the six studies analyzed in this review, results showed that administration of MF, in either topical or systemic form, reduced bone resorption ([@b0160], [@b0175], [@b0025], [@b0110], [@b0180], [@b0170]). However, only one animal study investigated the systemic administration of MF in animals ([@b0110]) and none of the clinical trials investigated the effect of systemic administration of MF on periodontal bone loss in humans. Nevertheless, in 100% of the RCTs, local intrabony administration of MF following SRP resulted in better clinical and radiographic parameters compared to SRP + 0% MF ([@b0175], [@b0180], [@b0170]). In one study, OFD + 1%MF + PRF resulted in significantly better outcomes than OFD, PRF + OFD and 1% MF + OFD, indicating that MF augments the regenerative effects of PRF ([@b0160]).

The effect of MF on osteoblasts *in vitro* was revealed previously ([@b0045], [@b0100]). In a study by Cortizo et al., exposing osteoblast-like cell lines to MF increased proliferation of the cells as well as higher alkaline phosphatase activity and an increased collagen-II turn over were observed ([@b0045]). Moreover, MF induced formation of mineralized bone tissue for up to 3 weeks. In a study by Kanazawa et al., osteoblast-like cells cultured with MF exhibited increased proliferation by the activation of AMP-activated protein kinase (AMPK) ([@b0100]). Additionally, the cells increased expressions of endothelial nitric oxide synthase (eNOS) and bone morphogenetic protein-2 (BMP-2) were detected. eNOS has a vital role in maintaining and controlling bone turnover ([@b0040], [@b0020]). BMP-2 is also known to increase osteoblast differentiation and bone formation ([@b0080]). Hence, results obtained in *in vitro* studies indicate that MF has an osteogenic effect which is triggered by the increased proliferation of osteoblasts.

The animal studies showed that MF has, both, a stimulatory effect on osteoblasts and an inhibitory effect on osteoclasts ([@b0025], [@b0110]). In the 10-day study by Bak et al. using periodontitis model, IP injections of MF stimulated the proliferation of osteoblasts with little effect on osteoclasts and adipocytes ([@b0025]). These results are similar to the increased osteoblast proliferation observed in the aforementioned *in vitro* studies ([@b0045], [@b0100]). However, in the 28-day study by Liu et al., MF had negligible effect on osteoblasts but decreased RANKL/OPG ratios and, hence, inhibited proliferation of osteoclasts ([@b0110]). Hence, to date, the mode of action of MF is unclear and more long-term studies are needed to better-understand the mechanism of osteogenic effect of the drug.

MF has been known to prevent fractures in diabetic patients, indicating its osteogenic effect similar to that observed in animal models and *in vitro* studies ([@b0185], [@b0235]). Hence, it is not surprising that intrabony injections of MF in a gel carrier augments the effect of surgical and non-surgical periodontal therapy and leads to increased IBD fill and reduced IBD as well as significant improvements in RAL/CAL, PD and GML ([@b0160], [@b0175], [@b0180], [@b0170]). According to results obtained in the study by Pradeep et al., 1% MF is the optimal concentration in the management of periodontitis ([@b0170]). It has also been observed that MF and PRF are more effective in improving outcomes when placed in intrabony defects following OFD than PFD, PRF or MF alone, suggesting that MF may augment the effect of PRF ([@b0160]). PRF is autologous plasma derivative containing fibrin and growth factors which has been previously used to restore intrabony defects due to its regenerative and space maintaining effects ([@b0165]). Combining MF with currently available GTR materials and scaffolds may provide additional effective options to manage periodontitis. However, more research is warranted to explore this hypothesis.

It is known that smoking has an adverse effect on periodontal health ([@b0065]). Based on the results obtained in the study by Rao et al., MF may prove to be a potent drug for improving outcomes following SRP in smokers ([@b0180]). Because smoking has a negative effect on the outcomes of periodontal regenerative therapy as well ([@b0150]), the effect of MF on the outcomes of implant therapy, GTR and prosthodontic therapy in smokers needs to be investigated.

As shown in [Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}, metaanalysis carried on the human studies in this reviewed indicates that MF increases the efficacy of surgical and non-surgical periodontal therapy. However, the I^2^ analysis showed that there was heterogenicity among the results obtained in studies. The RCTs included in this study have additional; limitations. The patients were followed-up for more than 9 months ([@b0160], [@b0175], [@b0180], [@b0170]). Therefore, the long-term efficacy of MF in improving the outcomes of periodontal disease is unknown. Furthermore, none of studies included histological analysis or bacterial studies which are crucial for accurate assessment of attachment loss ([@b0085]). Hence, it is unknown what effect MF has on human periodontal tissues at the microscopic level and on the bacterial flora of the periodontal pockets. Moreover, only one study included smokers ([@b0180]) and none of the studies included diabetic patients. Hence, studies focusing on the long-term outcome of MF on smokers and diabetic patients need to be conducted.

5. Conclusion {#s0075}
=============

Metformin is an effective medicament in improving the outcomes of surgical and non-surgical periodontal therapy. However, owing to the lack of histological and bacterial studies and short follow-up periods of reported studies, there is risk of bias in the RCTs and long-term efficacy of metformin in the treatment of intra bony defects is not yet ascertained. Further research is required to envisage long-term efficacy of metformin for chronic periodontitis management.
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[^1]: CT, computer tomography; IM, intramuscular injection; IP, intraperitoneal injection; RANKL, receptor activator of nuclear factor kappa-B ligand; OPG, osteoprotegerin

[^2]: IBDs, intrabony defects; MF, metformin gel; OFD, open-flap debridement; PRF, platelet-rich fibrin; RCT, randomized control trial; SRP, scaling and root planing.
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